Table 4.
Association of apolipoprotein A-IV with fatal cancer during the prospective follow-up and without a history of cancer at the baseline investigation (4424 out of 5039 patients)a
| HR | 95% CI | p-value | ||
|---|---|---|---|---|
| Calculations per 10 mg/dL increment of apoA-IV concentrations | ||||
| Model 1: 62 casesb | 0.60 | 0.43–0.85 | 0.003 | |
| Model 2: 60 casesb | 0.62 | 0.44–0.88 | 0.007 | |
| Calculations per quartile of ApoA-IV concentrations | ||||
| Model 1 | Quartile 1 (21 cases)b | 1.00 | ||
| Quartile 2 (11 cases)b | 0.42 | 0.20–0.87 | 0.02 | |
| Quartile 3 (19 cases)b | 0.60 | 0.32–1.14 | 0.12 | |
| Quartile 4 (11 cases)b | 0.32 | 0.14–0.71 | 0.005 | |
| Model 2 | Quartile 1 (19 cases)b | 1.00 | ||
| Quartile 2 (11 cases)b | 0.46 | 0.22–0.98 | 0.04 | |
| Quartile 3 (19 cases)b | 0.65 | 0.34–1.26 | 0.21 | |
| Quartile 4 (11 cases)b | 0.35 | 0.15–0.79 | 0.01 | |
Model 1: adjusted for age, sex, eGFRcystatin-C, ln-urine albumin-creatinine ratio
Model 2: as model 1 plus statin use, smoking, BMI, diabetes
Abbreviations: HR hazard ratio, CI confidence interval
aPatients with a history of cancer at the time of enrollment were not considered in this analysis
b“Cases” refers to the number of patients with fatal cancer events. Differences in number of cases between model 1 and 2 are explained by few patients with some missing covariates for model 2